Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese
Launched by SHANGHAI 10TH PEOPLE'S HOSPITAL · Jun 23, 2022
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how hidden damage to organs in Chinese adults may relate to future heart problems. Researchers want to see if using digital health tools—like apps or online programs—can help prevent or slow down this damage and reduce the risk of heart disease. The study aims to gather important information that can lead to better heart health for everyone.
To join the trial, participants need to be at least 18 years old and willing to commit to follow-up over time. However, individuals with severe heart disease, advanced kidney disease, recent strokes, or certain cancers will not be able to participate. Those who join can expect regular check-ins and support through digital health resources, which could help them maintain their health and potentially prevent future heart issues. This study is not yet recruiting participants, but it represents an exciting opportunity to learn more about heart health in the community.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aged 18 years or older
- • willing to participate the study and sign informed consent
- • available for long-term follow-up
- Exclusion Criteria:
- • severe heart disease (NYHA IV)
- • stage 4 or 5 CKD
- • malignant tumors or with life expectancy less than 5 years
- • stroke within 3 months
- • refuse to participate the study or not available for long-term follow up
About Shanghai 10th People's Hospital
Shanghai 10th People's Hospital, affiliated with Tongji University, is a leading clinical research institution in China known for its commitment to advancing medical science and improving patient care. With a focus on innovative therapies and cutting-edge research methodologies, the hospital conducts a wide range of clinical trials across various medical disciplines. Its state-of-the-art facilities and multidisciplinary team of experts enable rigorous study designs and high-quality data collection, fostering collaboration with both national and international partners. The hospital is dedicated to upholding ethical standards and promoting patient safety, ensuring that its clinical trials contribute significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Yi Zhang, PhD, MD
Principal Investigator
Shanghai 10th People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials